Prostate Cancer

Jabbari, Siavash; Hansen, Eric K.; Roach, Mack

doi:10.1007/978-0-387-92988-0_26

Cited by 2 publications

(2 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recommended guideline for the treatment of breast cancer is generally the use of two or more agents simultaneously or consecutively. Combination therapy is known to have a higher objective response rate and a longer time to progress than a single agent [ 27 , 28 ]. The most common chemotherapy regimen used was anthracycline-based.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of side effects and compliance to chemotherapy in breast cancer patients at a Nigerian tertiary hospital

Folorunso¹,

Abiodun²,

Abdus-salam³

et al. 2023

ecancer

View full text Add to dashboard Cite

Background: Chemotherapy improves tumour control and survival, but it may be associated with side effects (SEs) which can impair treatment compliance and worsen outcomes. Assessment of patients in routine clinical practice, outside clinical trials, may provide the information on effects of chemotherapy on patients and its impacts on treatment compliance.Aim: To assess the SE and compliance to chemotherapy in breast cancer patients.Methodology: A prospective study involving 120 breast cancer patients receiving chemotherapy was carried out at the oncology clinics of the University College Hospital Ibadan. SEs reported were recorded and graded using Common Toxicity Criteria for Adverse Events version 5. Compliance was defined as a receipt of planned cycles of chemotherapy in the planned doses within the planned duration. The data collected were analysed using the Statistical Package for the Social Sciences software version 25. Results:The patients were all females with a mean age of 51.2 ± 11.8 years. Patients reported between 2 and 13 SE with a median of 8 SE. Forty-two (35.0%) missed at least one course of chemotherapy while 78 (65%) were compliant. The reasons for non-compliance were deranged blood test 17 (14.2%), chemotherapy SE symptoms related 11 (9.1%), financial constraints 10 (8.3%), disease progression 2 (1.7%) and transportationrelated 2 (1.7%). Conclusion:Breast cancer patients encounter multiple SEs from chemotherapy which led to non-compliance with the treatment. Early identification and prompt treatment of these SEs will improve compliance with chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of side effects and compliance to chemotherapy in breast cancer patients at a Nigerian tertiary hospital

Folorunso¹,

Abiodun²,

Abdus-salam³

et al. 2023

ecancer

View full text Add to dashboard Cite

show abstract

“…Current strategies employed to improve outcomes include the addition of ADT and radiation dose escalation. Both strategies have successfully reduced biochemical failure rates: 3–6 months of neoadjuvant and concurrent ADT added to RT improves biochemical control by approximately 15%–25% across risk categories [79,82–86], whereas dose escalation to 78 to 80 Gy improves biochemical control by approximately 10%–20% [86–89]. However even with these improvements, biochemical failure rates remain poor for patients with higher risk localized disease and locally advanced disease; for example, after 4 months of neoadjuvant and concurrent ADT, 10-year biochemical failure rates were 28% and 31% for intermediate- and high-risk localized groups, respectively, in the recently published data from RTOG 94-08 [79].…”

Section: Prostate Cancer: Overview and Rationale For Targeted Radimentioning

confidence: 99%

Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy—Focus on Prostate Cancer

Alcorn

Walker

Gandhi

et al. 2013

IJMS

View full text Add to dashboard Cite

As our understanding of the molecular pathways driving tumorigenesis improves and more druggable targets are identified, we have witnessed a concomitant increase in the development and production of novel molecularly targeted agents. Radiotherapy is commonly used in the treatment of various malignancies with a prominent role in the care of prostate cancer patients, and efforts to improve the therapeutic ratio of radiation by technologic and pharmacologic means have led to important advances in cancer care. One promising approach is to combine molecularly targeted systemic agents with radiotherapy to improve tumor response rates and likelihood of durable control. This review first explores the limitations of preclinical studies as well as barriers to successful implementation of clinical trials with radiosensitizers. Special considerations related to and recommendations for the design of preclinical studies and clinical trials involving molecularly targeted agents combined with radiotherapy are provided. We then apply these concepts by reviewing a representative set of targeted therapies that show promise as radiosensitizers in the treatment of prostate cancer.

show abstract

Prostate Cancer

Cited by 2 publications

References 139 publications

Evaluation of side effects and compliance to chemotherapy in breast cancer patients at a Nigerian tertiary hospital

Evaluation of side effects and compliance to chemotherapy in breast cancer patients at a Nigerian tertiary hospital

Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy—Focus on Prostate Cancer

Contact Info

Product

Resources

About